Estudio de utilización y descripción de costes de eritropoyetina en pacientes hematológicos

There is a high percentage of therapy failures and inconsistency between erythropoietin use recommendations and clinical practice. This circumstance, as well as the high financial impact it entails, makes it essential that monitoring and follow- up strategies are implemented to contribute to an optimal usage of erythropoiesis stimulating factors.